|
|
|
|
|
|
|
|
| September 23, 2005 | Alligator Bioscience AB enters into drug development collaboration with major European pharmaceutical company.
| |
Lund, September 23, 2005 -Alligator Bioscience is pleased to announce the signing of a collaboration agreement with a major European pharmaceutical company for the optimizationof a protein, using Alligator´s proprietary single-stranded DNA recombination technology, FINDTM. According to the agreement Alligator Bioscience will receive up front and milestone payments for the pre-clinical development, as well as milestone payments during the clinical development of the final product.
Commenting on the agreement, Gun-Britt Fransson, CEO of Alligator Bioscience, says "We are very pleased to have entered into this agreement and look forward to building a fruitful and trusting relationship with our new partner. This deal will enable us to develop and to explore further the efficiency and uniqueness of the FINDTM technology while providing our customer with improved versions of the therapeutic protein”.
Alligator Bioscience uses its proprietary FINDTM technology to develop new therapeutic and diagnostic proteins and to optimize existing proteins. Since 2001, Alligator Bioscience has successfully collaborated with many companies in the pharmaceutical, diagnostic and biotech industry, improving customers’ proteins (such as antibodies and enzymes) and helping them to build more competitive pipelines. The Company has also created an internal pipeline of therapeutic drug candidates for major clinical indications, which are at varying stages of development. Alligator Bioscience operates from the Ideon Science Park in Lund, and has 22 employees. The Company has around 150 shareholders.
For more information
Alligator Bioscience AB
Gun-Britt Fransson
CEO
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| June 14, 2010 |
Alligator Bioscience AB appoints Sibylle Lenz as Chief Executive Officer
Read more >>
| |  |
| 15 april 2010 | Del 2 av riktad emission tillför Alligator Bioscience AB drygt 5 MSEK
Denna andra del av den riktade emissionen tillför Alligator Bioscience AB 5.025.000 SEK (av de 5,6 miljoner SEK som återstod av bemyndigandet som gavs vid årsstämman 2009. Emissionskursen, 15 kr per aktie, var samma som vid första delen av emissionen som genomfördes under 2009.
Antalet aktier som tillförs är 335.000. Totala antalet aktier efter emissionen är 15.285.820.
| | |
| 12 april 2010 | |
| | |
| 8 februari 2010 | Alternativa Aktiemarknaden har trots påtryckningar från Alligator Bioscience beslutat att ännu inte upphöra med noteringen på Alternativas handelsplats för onoterade aktier. Alligator vill därför åter klargöra att beslutet att inleda handel med Alligator Biosciences aktier skett utan någon som helst medverkan från bolagets sida. Alligator har uppmärksammat Finansinspektionen på den uppkomna situationen.
| | |
| 20 januari 2010 |
Alternativa aktiemarknadens initiativ
Alternativa aktiemarknaden har i januari 2010 beslutat inleda handel med Alligator Bioscience ABs aktier. Detta har skett utan Alligators medverkan och i strid med bolagets vilja. Alligator har bett Alternativa aktiemarknaden att upphöra med noteringen av bolagets aktier
| | |
| Januari 11, 2010 | Alligator Bioscience´s protein drug candidate ADC-1004 for treatment of ischemia reperfusion (I/R) injury reduced myocardial infarct size in a porcine model
| | Read more>>
| |
| December 2, 2009 | | Alligator Bioscience Awarded New Patent for its Protein Optimization Technology FIND® in Japan
| | Read more>>
| |
| 1 december 2009 | Per-Olof Mårtensson lämnar styrelsen
Per-Olof Mårtensson har, efter en lång och framgångsrik karriär inom internationell läkemedels, bioteknik och medicinsk teknisk industri, under de senaste åren valt att stegvis trappa ner sina engagemang och har nu beslutat sig för att lämna styrelsen för Alligator Bioscience AB.
| | Read more >>
| |
| 9 november 2009 | Vår företrädesemission är nu avslutad
Denna, tillsammans med den riktade emission vi hade tidigare under året, tillförde bolaget 41,5 miljoner kronor. Kursen var 15 kronor i båda emissionerna.
| | |
| 10 oktober 2009 | Samarbetsavtal med ett amerikanskt bioteknikbolag
Alligator Bioscience AB har tecknat ett samarbetsavtal med ett amerikanskt bioteknikbolag som utvecklar proteinläkemedel
| | Read More >>
| |
| 22 september 2009 | Redeye Company Report
Alligator Bioscience: Utvecklar nästa generations bioläkemedel
| | Read more >>
| |
| September 17, 2009 | | Alligator Bioscience enters into research and option agreement with BioInvent to jointly develop Antibody-based therapeutics for novel treatments for oncology indications
| | Read more>>
| |
| April 30, 2009 | | Biotecnol successfully completes milestone of process development and manufacturing activities for Alligator Bioscience AB inflammation programme ADC -1004
| Read more>>
| |
November 25, 2008
| Alligator Bioscience AB, the protein optimization company, to Present at the Rodman & Renshaw 10th Annual Healthcare Conference.
| | Read more >>
| |
| June 16, 2008 | Alligator Bioscience AB and PolyTherics Ltd announce strategic collaboration for optimisation of next generation biopharmaceuticals
| | Read more >>
| |
| February 18, 2008 | Alligator Bioscience and ImmuRx enter into strategic collaboration
| | Read more>>
| |
| November 9, 2007 | Alligator Bioscience strengthens its FIND® patent portfolio
| | Read more>>
| |
| September 17, 2007 | Alligator Bioscience and SARomics have entered into a collaboration agreement
| | Read more>>
| |
| September 11, 2007 | | Alligator Bioscience strengthens its FIND® patent portfolio
| | Read more>>
| |
| June 11, 2007 | Alligator Bioscience raises an additional 10,7 MSEK in second closing
| | Read more>>
| |
| May 29, 2007 | | Alligator Bioscience raises 51 MSEK in new share issue
| | Read more>>
| |
| April 20, 2007 | | Alligator Bioscience AB launches FINDbind™, an efficient method for affinity maturation of antibodies
| | Raed more>>
| |
| December 15, 2006 | | Alligator Bioscience AB has received a grant from Vinnova for further evaluations of the FIND® technology platform
| | Raed more>>
| |
| December 1, 2006 | | Alligator Bioscience AB and Axis-Shield ASA moves successful project into next phase
| | Read more>>
| |
| October 26, 2006 | | Alligator Bioscience AB has reached a successful milestone in its collaboration with Bayer HealthCare AG
| | Read more>>
| |
| October 09, 2006 | Alligator Bioscience to address immunogenicity with Epibase®
| | Raed more>>
| |
| September 23, 2005 | Alligator Bioscience AB enters into drug development collaboration with major European pharmaceutical company.
| | Read more>>
| |
| June 10, 2004 | | Alligator Bioscience concludes successful project for AstraZeneca
| | Read more>>
| |
| February 11, 2003 | | Alligator Bioscience and AB Enzymes enter into enzyme development collaboration
| | Read more>>
| |
| October 7, 2002 | | Alligator Bioscience and AstraZeneca enter into technology collaboration agreement regarding drug development
| | Read more>>
| |
|
|
|
|
|
|
|
|
|